A greater treatment response in younger patients is consistent with evidence for the benefits of early treatment of somatic signs and symptoms with IV idursulfase and the biological rationale for early treatment based on the relationship between progressive GAG storage and clinical manifestations in MPS II [28–31]. The gene discussed is IDS; the disease is mucopolysaccharidosis type 2.